[HTML][HTML] Novel treatments paradigms: membranous nephropathy

JE Rojas-Rivera, A Ortiz, FC Fervenza - Kidney international reports, 2023 - Elsevier
Primary membranous nephropathy (MN) is a kidney-specific autoimmune glomerular
disease and the leading cause of nephrotic syndrome (NS) in White adults, usually caused …

Vascular injury in glomerulopathies: the role of the endothelium

GSB Barbosa, NOS Câmara, FL Ledesma… - Frontiers in …, 2024 - frontiersin.org
In glomerulopathies, endothelial dysfunction and the presence of histological vascular
lesions such as thrombotic microangiopathy, arteriolar hyalinosis, and arteriosclerosis are …

[HTML][HTML] Complement factor I: Regulatory nexus, driver of immunopathology, and therapeutic

TM Hallam, SJ Sharp, A Andreadi, D Kavanagh - Immunobiology, 2023 - Elsevier
Complement factor I (FI) is the nexus for classical, lectin and alternative pathway
complement regulation. FI is an 88kDa plasma protein that circulates in an inactive …

[HTML][HTML] The Role of Complement in Kidney Disease: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

M Vivarelli, J Barratt, LH Beck Jr, F Fakhouri, DP Gale… - Kidney International, 2024 - Elsevier
Uncontrolled complement activation can cause or contribute to glomerular injury in multiple
kidney diseases. While complement activation plays a causal role in atypical hemolytic …

Novel approaches to primary membranous nephropathy: Beyond the KDIGO guidelines

Y Yang, K Cheng, G Xu - European Journal of Pharmacology, 2024 - Elsevier
Primary membranous nephropathy (PMN) is an immune-mediated glomerular disease.
Rituximab (RTX) is recommended as a first-line immunosuppressive therapy and shows …

PLA2G12B Mediates Arachidonic Acid Metabolism through Activation of the NF-κB Pathway to Promote Membrane Nephropathy

L Fu, J Ping, F Guo, J Song, M Luo… - Kidney and Blood Pressure …, 2023 - karger.com
Introduction: The disruption of podocyte structure and function are the main pathological
mechanism of membranous nephropathy (MN). Phospholipases A2, Group XII B …

Mutations in atypical hemolytic uremic syndrome provide evidence for the role of calcium in complement factor I

A Java, J Atkinson, Z Hu, N Pozzi - Blood, 2023 - ashpublications.org
Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy. Genetic
variants in complement proteins are found in≈ 60% of patients. Of these patients,≈ 15 …

移植肾血栓性微血管病的发病机制和诊疗进展

孙豪杰, 王锁刚 - 肾脏病与透析肾移植杂志, 2023 - njcndt.com
移植肾血栓性微血管病(TMA) 是肾移植术后的一种致死性并发症, 严重影响肾移植受者和移植肾
的长期生存. 移植肾TMA 可分为新发性TMA 和复发性非典型溶血性尿毒综合征(aHUS) …

[HTML][HTML] Клиническая характеристика и генетический профиль системы комплемента при почечной ТМА у пациентов с тяжелыми формами артериальной …

МИ Акаева, НЛ Козловская, ЛА Боброва… - Терапевтический …, 2024 - cyberleninka.ru
Обоснование. Круг заболеваний, характеризующихся развитием почечной
тромботической микроангиопатии (ТМА), включает в себя злокачественную …

Clinical characteristics and genetic profile of complement system in renal thrombotic microangiopathy in patients with severe forms of arterial hypertension

MI Akaeva, NL Kozlovskaya, LA Bobrova… - Terapevticheskii …, 2024 - ter-arkhiv.ru
Background. The spectrum of diseases characterized by the development of renal
thrombotic microangiopathy (TMA) encompasses the malignant hypertension (MHT). TMA in …